Barclays
OVID icon

Barclays’s Ovid Therapeutics OVID Stock Holding History

Barclays’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 4995
2025
Q4 		$2 Sell
1
-70
-99% -$108 ﹤0.01% 5182
2025
Q3 		$92 Hold
71
– – ﹤0.01% 5282
2025
Q2 		$23 Sell
71
-63,847
-100% -$19.2K ﹤0.01% 5142
2025
Q1 		$19.9K Sell
63,918
-29,389
-31% -$18.1K ﹤0.01% 4790
2024
Q4 		$87.1K Buy
93,307
+9,132
+11% +$10.2K ﹤0.01% 4627
2024
Q3 		$99.3K Buy
84,175
+63,702
+311% +$66.6K ﹤0.01% 4576
2024
Q2 		$15.7K Sell
20,473
-21,663
-51% -$60.3K ﹤0.01% 4475
2024
Q1 		$129K Sell
42,136
-39,924
-49% -$134K ﹤0.01% 4339
2023
Q4 		$264K Buy
82,060
+71,280
+661% +$244K ﹤0.01% 4287
2023
Q3 		$41.4K Sell
10,780
-1,175
-10% -$4.22K ﹤0.01% 3948
2023
Q2 		$39.2K Buy
+11,955
New +$40.6K ﹤0.01% 3933
2021
Q4 		– Sell
-8,218
Closed -$28K – 4568
2021
Q3 		$28K Sell
8,218
-27,009
-77% -$98.5K ﹤0.01% 4289
2021
Q2 		$137K Sell
35,227
-4,850
-12% -$19.1K ﹤0.01% 3716
2021
Q1 		$161K Buy
40,077
+24,718
+161% +$82.1K ﹤0.01% 3806
2020
Q4 		$35K Sell
15,359
-10,276
-40% -$47.9K ﹤0.01% 4546
2020
Q3 		$147K Buy
25,635
+2,061
+9% +$13.8K ﹤0.01% 4037
2020
Q2 		$173K Buy
+23,574
New +$110K ﹤0.01% 4170
2019
Q3 		– Sell
-267
Closed – – 7013
2019
Q2 		$0 Sell
267
-3,456
-93% -$6.17K ﹤0.01% 7161
2019
Q1 		$7K Buy
+3,723
New +$9.31K ﹤0.01% 6646
2018
Q4 		– Sell
-4,938
Closed -$28K – 7224
2018
Q3 		$28K Buy
4,938
+3,518
+248% +$26.7K ﹤0.01% 6343
2018
Q2 		$11K Sell
1,420
-1,118
-44% -$9.6K ﹤0.01% 6507
2018
Q1 		$18K Buy
2,538
+1,737
+217% +$14.1K ﹤0.01% 6469
2017
Q4 		$8K Buy
801
+683
+579% +$6.27K ﹤0.01% 6570
2017
Q3 		$1K Buy
118
+114
+2,850% +$949 ﹤0.01% 6761
2017
Q2 		$0 Buy
+4
New +$52 ﹤0.01% 6849

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Barclays's OVID Position: Q1 2026 in Review

Barclays held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4995.

Barclays first reported a position in OVID in Q2 2017 and has held it in 26 quarters since. The position peaked at $264K in Q4 2023. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Barclays held 1 share of Ovid Therapeutics worth $2 as of Q1 2026.
  • Barclays left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4995 holding.
  • Barclays first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • Barclays's Ovid Therapeutics position peaked at $264K in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.